89bio Inc (NAS:ETNB)
$ 8.855 0.385 (4.55%) Market Cap: 937.83 Mil Enterprise Value: 433.80 Mil PE Ratio: 0 PB Ratio: 1.73 GF Score: 36/100

89Bio Inc at Bank of America Global Healthcare Conference Transcript

May 09, 2023 / 09:35PM GMT
Release Date Price: $18.07 (+3.85%)
Geoff Meacham
Bank of America - Analyst

So we have -- I'm Geoff Meacham, the Biopharma Analyst here at B of A. We're thrilled to have 89bio. Rohan is up on the stage with me. So thank you for coming.

Rohan Palekar
89bio, Inc. - CEO

Yeah. Thanks for having us.

Questions & Answers

Geoff Meacham
Bank of America - Analyst

Of course, yeah. So maybe just give us a status update on NASH following recent data, and what we could expect more from --? I'm assuming that [Easel] will coming up.

Rohan Palekar
89bio, Inc. - CEO

Sure. So I just mentioned we had our NASH Phase 2b results read out in the end of March. And we are incredibly excited about the data we've put out with pegozafermin.

So for background who don't know, our company is late-stage clinical company focused liver and cardio-metabolic diseases. And our lead program is pegozafermin. And this is the FGF21 analog, which we believe has the potential to be transformational in these indications.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot